CanaryBio Confirms 25% Partial Remission in First Treatment Patients with Oregovomab

[Asia Economy Reporter Jang Hyowon] Canaria Bio (CEO Nahanik) received approval for the compassionate use of the ovarian cancer treatment drug Oregobomab and began administering it last month to five terminal cancer patients with no alternative treatment options. Oregobomab will be administered a total of four times.

Among the five approved patients, three died while waiting for the treatment, and two started receiving Oregobomab.

The first patient, in their late 50s, showed a 25% reduction in tumor diameter on a CT scan after the first dose. This patient had already undergone five rounds of treatment including various cytotoxic anticancer drugs, PARP inhibitors, angiogenesis inhibitors, and immune checkpoint inhibitors, but showed no further improvement. This Oregobomab administration is the sixth treatment. The patient completed the second treatment last week and testified that they are living a normal life this week, including receiving personal training from a trainer.

Professor Choi Jongkwon of Konyang University Hospital, who is leading the compassionate use treatment, emphasized, “It is an encouraging result that more than 20% of patients who no longer respond to existing anticancer drugs showed partial remission.”

This content was produced with the assistance of AI translation services.